CONMED Co. (CNMD) CFO Luke A. Pomilio Sells 18,023 Shares

CONMED Co. (NASDAQ:CNMD) CFO Luke A. Pomilio sold 18,023 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $63.38, for a total transaction of $1,142,297.74. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of CONMED Co. (CNMD) traded down $1.68 during trading hours on Monday, reaching $61.53. 219,941 shares of the company traded hands, compared to its average volume of 185,441. CONMED Co. has a twelve month low of $39.74 and a twelve month high of $64.99. The firm has a market cap of $1,765.70, a P/E ratio of 31.88, a P/E/G ratio of 2.57 and a beta of 0.74. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.56 and a quick ratio of 1.49.

CONMED (NASDAQ:CNMD) last issued its earnings results on Wednesday, January 31st. The medical technology company reported $0.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.04. CONMED had a net margin of 6.97% and a return on equity of 9.15%. The business had revenue of $222.60 million during the quarter, compared to the consensus estimate of $212.17 million. During the same period last year, the business posted $0.54 EPS. CONMED’s revenue was up 9.1% on a year-over-year basis. equities research analysts anticipate that CONMED Co. will post 2.14 earnings per share for the current year.

A number of equities analysts have recently commented on the stock. BidaskClub upgraded shares of CONMED from a “sell” rating to a “hold” rating in a research note on Friday. Zacks Investment Research upgraded shares of CONMED from a “hold” rating to a “buy” rating and set a $71.00 target price for the company in a research note on Friday. Needham & Company LLC raised their target price on shares of CONMED from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Thursday. Piper Jaffray Companies reiterated a “hold” rating and issued a $46.00 target price on shares of CONMED in a research note on Friday, November 3rd. Finally, KeyCorp reiterated a “hold” rating on shares of CONMED in a research note on Friday, November 3rd. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. CONMED has a consensus rating of “Hold” and a consensus target price of $59.00.

Large investors have recently modified their holdings of the stock. Piedmont Investment Advisors LLC acquired a new stake in CONMED in the 2nd quarter valued at about $273,000. Macquarie Group Ltd. lifted its position in CONMED by 13.9% during the third quarter. Macquarie Group Ltd. now owns 731,957 shares of the medical technology company’s stock worth $38,406,000 after acquiring an additional 89,078 shares during the last quarter. Prudential Financial Inc. lifted its position in CONMED by 65.8% during the third quarter. Prudential Financial Inc. now owns 118,365 shares of the medical technology company’s stock worth $6,211,000 after acquiring an additional 46,956 shares during the last quarter. Rothschild Asset Management Inc. lifted its position in CONMED by 52.5% during the third quarter. Rothschild Asset Management Inc. now owns 53,721 shares of the medical technology company’s stock worth $2,819,000 after acquiring an additional 18,489 shares during the last quarter. Finally, Epoch Investment Partners Inc. lifted its position in CONMED by 2.1% during the third quarter. Epoch Investment Partners Inc. now owns 232,576 shares of the medical technology company’s stock worth $12,203,000 after acquiring an additional 4,839 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.com-unik.info/2018/02/05/conmed-co-cnmd-cfo-luke-a-pomilio-sells-18023-shares.html.

CONMED Company Profile

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Insider Buying and Selling by Quarter for CONMED (NASDAQ:CNMD)

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit